Medpace Holdings Inc. (MEDP) experienced a significant 24-hour decline of 5.35% during Tuesday's trading session.

The clinical research organization's stock fell sharply despite reporting fourth-quarter revenue and earnings that exceeded analyst expectations. The sell-off appears to have been driven by investor concerns over contracting profitability, as the company's net income margin decreased compared to the prior year. Furthermore, Medpace's revenue guidance for the full year 2026 came in around the midpoint of consensus estimates, failing to deliver a positive surprise that could have supported the stock price.